(Information sent by the signatory company)
– Myonex Announces Acquisition of SaveWay Compounding Pharmacy to Expand Clinical Trial Services Throughout the United States
HORSHAM, Pa., April 9, 2024 /PRNewswire/ — Myonex, a leading global clinical trial supply company, has completed the acquisition of SaveWay Compounding Pharmacy of Newark, Delaware. The pharmacy will operate as SaveWay Compounding Pharmacy, a Myonex company.
In a further effort to support the trial designs of clinical trial sponsors with direct-to-patient (DTP) capabilities and home health providers (HHP), this acquisition enables broader access to patients across the United States, in addition to support patients with their access to trial medications and necessary equipment.
“SaveWay’s pharmaceutical capabilities complement and expand Myonex’s existing clinical supply solutions in the United States. SaveWay will provide additional access for medication supply and direct-to-patient options in all 50 states for our clinical packaging and labeling services and ancillary supplies.” SaveWay complements the leading Myonex -CTRx™ market to ensure a complete set of prescription dispensing options for access to investigational medicines (IMPs) and commercial medicines throughout the U.S. These additional capabilities allow Myonex to better meet needs. of our customers and enable decentralized clinical trials (DCT) and hybrid studies,” said James Lovett, CEO of Myonex.
“With this acquisition, Myonex will support SaveWay’s expansion into clinical trials and accelerate the growth of direct-to-patient services. SaveWay has a unique opportunity to grow and expand care for patients across the United States in clinical trials by dispensing investigational medicinal products and commercial medicinal products and specialty compounded medicinal products directly to clinical trial patients. We welcome the opportunity to be part of an experienced clinical trial supply company with roots in pharmacy. Myonex understands how we work and what we can offer to support current trends in clinical trials,” explained Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay.
The recent acquisition announcement of Creapharm, and now SaveWay, accelerates Myonex’s overall commitment to continue to be faster, more flexible and reliable for customers, while improving the patient experience in clinical trials. This growth positions Myonex as an industry partner with one of the most diverse clinical trial supply service offerings globally.
Myonex was exclusively advised by Crosstree as financial advisor and Troutman Pepper as legal advisor in the acquisition of SaveWay.
About Myonex
Myonex is a leading global full clinical trial supply company, offering customized solutions in drug sourcing, packaging, labeling and supply of central and local equipment and accessories to support the specific requirements and complexities of each trial. With nine locations in the United States, Germany, United Kingdom, and France, we partner with pharmaceutical and biotechnology companies, contract research organizations (CROs), and other clinical trial service providers seeking a flexible, comprehensive solution for their clinical trials needs. essay supply. Learn more at www.myonex.com.
About SaveWay
SaveWay Compounding Pharmacy was founded as a local community resource for affordable non-sterile compounded medications. Today it offers custom sterile and non-sterile compounded medications that can be customized by dosage or delivery system. Learn more at www.savewaypharmacy.com/.
CONTACT:Renea Miller214-605-2749
Logo – https://mma.prnewswire.com/media/2381955…
View original content: https://www.prnewswire.com/news-releases/myonex-anuncia-la-adquisicion-de-saveway-compounding-pharmacy-302111453.html
